Nuveen’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-85,940
| Closed | -$487K | – | 3292 |
|
|
2025
Q3 | $487K | Buy |
85,940
+9,789
| +13% | +$50.1K | ﹤0.01% | 2904 |
|
|
2025
Q2 | $290K | Sell |
76,151
-14,352
| -16% | -$44.6K | ﹤0.01% | 3069 |
|
|
2025
Q1 | $238K | Hold |
90,503
| – | – | ﹤0.01% | 3085 |
|
|
2024
Q4 | $320K | Sell |
90,503
-89,150
| -50% | -$341K | ﹤0.01% | 3112 |
|
|
2024
Q3 | $819K | Buy |
179,653
+89,150
| +99% | +$431K | ﹤0.01% | 2843 |
|
|
2024
Q2 | $394K | Hold |
90,503
| – | – | ﹤0.01% | 3072 |
|
|
2024
Q1 | $454K | Hold |
90,503
| – | – | ﹤0.01% | 3006 |
|
|
2023
Q4 | $567K | Hold |
90,503
| – | – | ﹤0.01% | 2964 |
|
|
2023
Q3 | $644K | Hold |
90,503
| – | – | ﹤0.01% | 2758 |
|
|
2023
Q2 | $922K | Buy |
+90,503
| New | +$945K | ﹤0.01% | 2697 |
|
|
2021
Q2 | – | Sell |
-32,739
| Closed | -$218K | – | 3513 |
|
|
2021
Q1 | $218K | Hold |
32,739
| – | – | ﹤0.01% | 3216 |
|
|
2020
Q4 | $173K | Hold |
32,739
| – | – | ﹤0.01% | 3211 |
|
|
2020
Q3 | $244K | Hold |
32,739
| – | – | ﹤0.01% | 3122 |
|
|
2020
Q2 | $241K | Buy |
+32,739
| New | +$288K | ﹤0.01% | 3065 |
|
Nuveen's SCPH Position: Q4 2025 in Review
Nuveen sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 85,940 shares — an estimated $487K sold.
Nuveen first reported a position in SCPH in Q2 2020 and held it in 14 quarters. The position peaked at $922K in Q2 2023. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- Nuveen reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Nuveen sold 85,940 scPharmaceuticals shares in Q4 2025, an estimated $487K.
- Nuveen first reported a position in scPharmaceuticals in Q2 2020 and held it in 14 quarters.
- Nuveen's scPharmaceuticals position peaked at $922K in Q2 2023.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on Nuveen's 13F filing for Q4 2025, filed 12 Feb 2026.